Hypertension is the most prevalent cardiovascular disease affecting 20-50 % of the adult population.
A later publication from the HOT study showed gender differences in the preventive effect of ASA, which significantly reduced myocardial infarction only in men by 42 %; but the reduction in myocardial infarction was only 19 %, and thus not significant in women. This was due to less statistical power when subdivided into men and women. 8 Subgroup-treatment interaction analyses indicated that only patients with serum creatinine >1.3 mg/dl had a significantly greater reduction of CV events and myocardial infarction, while the risk of bleeding was not significantly different between the subgroups. 9 A favourable balance between benefit and harm of ASA was documented in subgroups of patients at higher global baseline risk and baseline systolic blood pressure (≥180 mmHg).
More recently, the benefit of ASA was significantly greater in a subgroup with low estimated glomerular filtration rate (eGFR) (<45 ml/min/1.73 m 2 ), for which an increased risk of major bleeding appears to be outweighed by substantial benefit. 10 
Cochrane Collaboration Review of Antiplatelet Agents For Hypertension
Lip et al. found four trials including a total of 44,012 patients to be subject of the meta-analysis. 11 ASA did not reduce stroke or all CV events compared with placebo in primary prevention patients with elevated blood pressure and no prior CV disease. On the other hand, myocardial infarction was reduced with ASA in primary prevention; however, the benefit was negated by harm of similar magnitude due to an increase in major haemorrhage.
The benefit of antiplatelet therapy for secondary prevention in patients with hypertension is many times greater than the harm.
No benefit for warfarin therapy alone or in combination with ASA was found in patients with elevated blood pressure. Diclopidine, clopidogrel and newer antiplatelet agents (prasugrel, ticagrelor) have not been sufficiently evaluated in patients with hypertension.
There is a need for further trials evaluating antithrombotic therapy, including newer agents in hypertension.
European Society of Hypertension/European Society of Cardiology Guidelines
The 2013 European Society of Hypertension (ESH)/European Society of Cardiology guidelines 12 concluded that antiplatelet therapy, particularly low-dose ASA, should be prescribed to controlled hypertensive patients with previous CV events and should be considered in hypertensive patients with reduced renal function or a high CV risk.
ASA is not recommended in low-to-moderate risk hypertensive patients in whom absolute benefit and harm are equivalent.
Acetylsalicylic Acid in Preventing Pre-eclampsia
Pre-eclampsia (defined as de novo appearance of hypertension in pregnancy accompanied by proteinuria >0.3 g/24 hours) is associated with increased risk of maternal, foetal and neonatal morbidity and mortality. A reliable prediction of development of this condition has so far failed. A meta-analysis by Duley et al. 13 showed only a mild risk reduction of developing pre-eclapmsia with low-dose ASA. Therefore, low-dose of ASA was only recommended in pregnant women at high risk of developing pre-eclampsia defined as a history of pre-eclampsia presenting before 28 weeks of gestation. Increased angiotensin II sensitivity predisposes to hypertension and plaque instability. The increased sensitivity to angiotensin II in healthy young subjects with isolated hypercholesterolaemia can be partly restored by therapy to reduce the levels of LDL-cholesterol using statins. There is evidence that statins downregulate angiotensin II type 1 (AT 1 )-receptor expression. 19 Clinical trials have demonstrated that aggressive treatment with statins improves serum creatinine, glomerular filtration rate and urate levels. 20, 21 This effect is probably another consequence of improved blood flow following treatment with statins. The beneficial effect of statins in preventing renal dysfunction has also been documented and seems to be independent of their lipid-lowering effect. 22 Statins significantly reduce albuminuria or proteinuria and are associated with a small reduction in the rate of kidney function loss, particularly in populations with CV disease. 23 
Effects of Statins on Blood Pressure in Clinical Studies
Most of the studies report a small reduction in blood pressure; however, the blood pressure-lowering effect of statins is not consistent. 26 As this effect was seen in patients not receiving antihypertensive treatment (most patients were normotensive), these results are compatible with the above possibility that statins exert a small BP-lowering effect that can be detected only when they are given alone.
By contrast, in the Plaque Hypertension Lipid-Lowering Italian
Study (PHYLLIS), a randomised, placebo-controlled, double-blind study including 508 patients with mild hypertension and hypercholesterolaemia, administration of a statin (pravastatin 40 mg once daily) in hypertensive patients with BP effectively reduced by concomitant antihypertensive treatment did not have an additional BP-lowering effect. 27 The strengths of this study were a 2.6-year follow-up and ambulatory BP monitoring in addition to clinic BP measurement.
A recent meta-analysis of 40 studies and 51 comparison groups 
Studies in Blood Pressure -Large Clinical Outcome Trials Statins and Blood Pressure -Implications of Large Clinical Outcome Trials
Treatment of hypertension is associated with a reduction in stroke and, to a lesser extent, coronary events. It is also well-known that elevated serum total cholesterol significantly increases CHD risk. Therefore, it is logical that co-existing vascular risk factors including abnormal lipid profiles should be an integral part of hypertension management.
The benefit of lowering both BP and cholesterol was evaluated in two large-scale trials: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) 29 and Anglo-Scandinavian Cardiac Outcomes Trial -Lipid-Lowering Arm (ASCOT-LLA). 30 Part of ALLHAT was designed to determine whether pravastatin compared with usual care would reduce all-cause mortality in 10,355 patients with hypertension and moderate hypercholesterolaemia, plus at least one additional CHD risk factor. 29 At four years, total cholesterol was reduced by 17.2 % with pravastatin versus 7.6 % with usual care.
All-cause mortality was similar in the two groups and CHD event rates
were not different between the two groups; six-year CHD event rates were 9.3 % (pravastatin) and 10.4 % (usual care). These results could be attributed to the small difference in total cholesterol (9.6 %) and LDL-cholesterol (16.7 %) between pravastatin and usual care compared with other statin trials. Adherence to the treatment assigned declined over time. For those assigned to pravastatin, adherence dropped from 87.2 % at year two to 80 % at year four, and 77 % at year six, although the number of participants was small. On the other hand, in the usual care group, crossovers to statin treatment increased from 8 % at year two to 17 % by year four. This increase continued at year six, but the number of participants was small.
In the Anglo-Scandinavian Cardiac Outcomes Trial -Blood Pressure-Lowering Arm (ASCOT-BPLA) trial, 30 19,342 men and women with hypertension and at least three other CV risk factors were randomised to amlodipine (5-10 mg/d) ± perindopril (4-8 mg/d) or to atenolol (50-100 mg/d) ± bendroflumethiazide (1.25-2.5 mg/d). A total of 10,305 of these patients with normal or slightly elevated total cholesterol were randomised to atorvastatin 10 mg/d or placebo. 17 The atorvastatin arm was stopped prematurely at 3.3 years due to a significant reduction in the primary endpoint (-36 %; p=0.0005) (see Figure 1) . The benefit of atorvastatin treatment was apparent within the first year of treatment. Fatal/ non-fatal stroke and total CV/coronary events were also reduced with atorvastatin. At one year, atorvastatin reduced total cholesterol by 24 % and LDL-cholesterol by 35 %. However, in the period between six weeks and 18 months, a significant 1.1/0.7 mmHg difference in BP was seen in favour of atorvastatin regardless of titration of doses and numbers of drugs. Overall, amlodipine-perindopril therapy was superior to atenolol-bendroflumethiazide therapy, 30 and a further analysis of early monotherapy data comparing amlodipine with atenolol suggested a positive interaction between atorvastatin and amlodipine. 31 Compared with placebo, allocation to atorvastatin reduced the incidence of the primary endpoint significantly by approximately eight years after closure of the lipid-lowering arm (LLA), which may be due to legacy effect.
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A meta-analysis of large clinical trials, including only those with more than 1,000 patients followed for more than two years, was published by Messerli et al. 34 Besides ASCOT-LLA and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT), 12 trials enrolling 69,284 patients met the inclusion criteria. Overall, in these 12 trials, statin therapy decreased cardiac death by 24 % (RR 0.76; 95 % CI 0.71-0.82).
There was no evidence of a difference in RR estimates for hypertensive and normotensive patients. In conclusion, statin therapy effectively decreased CV morbidity and mortality to the same extent in hypertensive and normotensive patients.
European Society of Hypertension/European Society of Cardiology Guidelines
The 2013 ESH/ESC guidelines 12 recommend using statin therapy in hypertensive patients at moderate-to-high CV risk to achieve the target LDL cholesterol value <3 mmol/l (115 mg/dl). For individuals with manifest CV disease or at very high CV risk 35 a more aggressive LDL target of <1.8 mmol/l (70 mg/dl) is recommended. n
